Issues
Prediction of the efficacy of adjuvant radiotherapy for early endometrioid uterine cancer based on polymorphism of genes affecting oxidative stress
«Radiation and Risk», 2025, vol. 34, No. 3, pp.86-97
DOI: 10.21870/0131-3878-2025-34-3-86-97
Authors
Zamulaeva I.A. – Head of Dep., D. Sc., Biol., Prof. Contacts: 4 Korolyov str., Obninsk, Kaluga region, Russia, 249035. Tel.: (484) 399-71-88; e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. .Mkrtchian L.S. – Head of Dep., MD
Krikunova L.I. – Chief Researcher, MD, Prof.
Minaeva N.G. – Lead. Researcher, C. Sc., Biol.
Tkachenko B.E. – Post-Grad. Student. A. Tsyb MRRC.
Kaprin A.D. – General Director, Director of P. Hertsen MORI, Head of RUDN University Dep., Academician of RAS, MD, Prof. NMRRC.
1 A. Tsyb MRRC, Obninsk
2 Joint Institute for Nuclear Research, Dubna
3 Peoples' Friendship University of Russia named after Patrice Lumumba, Moscow
4 P. Hertsen MORI, Moscow
5 NMRRC, Obninsk
Abstract
Uterine cancer (UC) ranks first among malignant neoplasms of the female reproductive system. Despite the high proportion of early detection, the effectiveness of adjuvant radiotherapy remains variable, which necessitates the search for molecular prognostic markers. In this study, we assessed the prognostic significance of single nucleotide polymorphisms (SNPs) of genes regulating oxidative stress in the context of disease-free survival (DFS) in patients with stage I endometrioid UC who received combined treatment. The study included 93 patients who underwent surgery and adjuvant radiotherapy. Genotyping of common polymorphic variants of the APOE (rs429358, rs7412), COMT (rs4680), HFE (rs1800562) and PON-1 (rs662) genes was performed using PCR with subsequent restriction. A statistically significant association was established between the rs662 genotype of the PON-1 gene and DFS (p=0.01), as well as pronounced trends for the COMT rs4680 and HFE rs1800562 polymorphisms. The multiple regression model including these SNPs demonstrated a high correlation with DFS (R=0.99; p<0.00001). However, discriminant analysis did not reveal sufficient prognostic value of the model for clinical use. The obtained results indicate a potential role of polymorphisms of genes controlling oxidative stress in predicting the response to radiotherapy in patients with stage I endometrioid radiotherapy after surgical treatment, but require confirmation in larger studies.
Key words
radiobiology, oncology and radiotherapy, uterine cancer, prognosis of treatment effectiveness, oxidative stress, reactive oxygen species, genetic polymorphism, APOE, COMT, HFE, PON-1.
References
1. Malignant neoplasms in Russia in 2023 (morbidity and mortality). Eds.: A.D. Kaprin, V.V. Starinskiy, G.V. Pe-trova. Moscow, P. Herzen MORI, 2024. 276 p. (In Russian).
2. Aoki Y., Kanao H., Wang X., Yunokawa M., Omatsu K., Fusegi A., Takeshima N. Adjuvant treatment of endometrial cancer today. Jpn. J. Clin. Oncol., 2020. vol. 50, no. 7, pp. 753-765.
3. Drobin K., Marczyk M., Halle M., Danielsson D., Papiez A., Sangsuwan T., Bendes A., Hong M.G., Qundos U., Harms-Ringdahl M., Wersäll P., Polanska J., Schwenk J.M., Haghdoost S. Molecular profiling for predictors of radiosensitivity in patients with breast or head-and-neck cancer. Cancers (Basel), 2020, vol. 12, no. 3, pp. 753. DOI: 10.3390/cancers12030753.
4. Khavari A.P., Liu Y., He E., Skog S., Haghdoost S. Serum 8-Oxo-dG as a predictor of sensitivity and out-come of radiotherapy and chemotherapy of upper gastrointestinal tumours. Oxid. Med. Cell. Longev., 2018, vol. 2018, pp. 4153574. DOI: 10.1155/2018/4153574.
5. Danielsson D., Brehwens K., Halle M., Marczyk M., Sollazzo, A., Polanska J., Munck-Wikland E., Wojcik A., Haghdoost S. Influence of genetic background and oxidative stress response on risk of mandibular osteoradionecrosis after radiotherapy of head and neck cancer. Head Neck, 2016, vol. 38, no. 3, pp. 387-393.
6. Sorolla M.A., Parisi E., Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers (Basel), 2020, vol. 12, no. 7, pp. 1906. DOI: 10.3390/cancers12071906.
7. de Aguiar B.R., Ferreira E.B., Normando A.G., Mazzeu J.F., Assad D.X., Guerra E.N., Reis P.E. Single nucleotide polymorphisms to predict acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol., 2022, vol. 173, pp. 103651. DOI: 10.1016/j.critre-vonc.2022.103651.
8. Averbeck D., Candéias S., Chandna S., Foray N., Friedl A.A., Haghdoost S., Jeggo P.A., Lumniczky K., Paris F., Quintens R., Sabatier L. Establishing mechanisms affecting the individual response to ionizing radiation. Int. J. Radiat. Biol., 2020, vol. 96, no. 3, pp. 297-323.
9. Pavlopoulou A., Bagos P.G., Koutsandrea V., Georgakilas A.G. Molecular determinants of radiosensitivity in normal and tumor tissue: a bioinformatic approach. Cancer Lett., 2017, vol. 403, pp. 37-47.
10. Córdoba E.E., Abba C.M., Lacunza E., Fernández E., Güerci A.M. Polymorphic variants in oxidative stress genes and acute toxicity in breast cancer patients receiving radiotherapy. Cancer Res. Treat., 2016, vol. 48, no. 3, pp. 948-954.
11. Zharikova I.A., Kondrashova T.V., Osokova E.A., Smirnova I.A. Radiation reactions of normal tissues in patients with breast cancer: relationship with allelic forms of the COMT gene. Radiatsiya i risk – Radiation and Risk, 2009, vol. 18, no. 4, pp. 60-72. (In Russian).
12. Sarhadi V.K., Armengol G. Molecular biomarkers in cancer. Biomolecules, 2022, vol. 12, no. 8, pp. 1021. DOI: 10.3390/biom12081021.
13. Domenicotti C., Marengo B. Paradox role of oxidative stress in cancer: state of the art. Antioxidants (Basel), 2022, vol. 11, no. 5, pp. 1027. DOI: 10.3390/antiox11051027.
14. Forman H.J., Zhang H. Targeting oxidative stress in disease: promise and limitations of antioxidant therapy. Nat. Rev. Drug. Discov., 2021, vol. 20, no. 9, pp. 689-709.
15. Weinberg F., Ramnath N., Nagrath D. Reactive oxygen species in the tumor microenvironment: an overview. Cancers (Basel), 2019, vol. 11, no. 8, pp. 1191. DOI: 10.3390/cancers11081191.
16. Hao S. Cai D., Gou S., Li Y., Liu L., Tang X., Chen Y., Zhao Y., Shen J., Wu X., Li M., Chen M., Li X., Sun Y., Gu L., Li W., Wang F., Cho C.H., Xiao Z., Du F. Does each component of reactive oxygen species have a dual role in the tumor microenvironment? Curr. Med. Chem., 2024, vol. 31, no. 31, pp. 4958-4986.
17. Taghizadeh-Hesary F. “Reinforcement” by tumor microenvironment: the seventh “R” of radiobiology. Int. J. Radiat. Oncol. Biol. Phys., 2024, vol. 119, no. 3, pp. 727-733.
18. Lumsden A.L. Mulugeta A., Zhou A., Hyppönen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study. eBioMedicine, 2020, vol. 59, pp. 102954. DOI: 10.1016/j.ebiom.2020.102954.
19. Xu S., Wu N., Liu X., Zhu J., Liu Zh. The catechol-O-methyltransferase (COMT) Val158Met polymorphism is associated with oxycodone requirements, adverse effects, and pain sensitivity in cancer patients. J. Clin. Pharm. Ther., 2024, vol. 2024, no. 1, pp. 9990112. DOI: 10.1155/2024/9990112.
20. Katsarou M.S., Latsi R., Papasavva M., Demertzis N., Kalogridis T., Tsatsakis A.M., Spandidos D.A., Drakoulis N. Population-based analysis of HFE gene polymorphisms and susceptibility to hereditary hemo-chromatosis. Mol. Med. Rep., 2016, vol. 14, no. 1, pp. 630-636.
21. Shizukuda Y., Rosing D.R. Hereditary hemochromatosis with homozygous C282Y HFE mutation: possible clinical model to assess effects of elevated reactive oxygen species on the development of cardiovascular disease. Mol. Cell. Biochem., 2024, vol. 479, no. 3, pp. 617-627.
22. Medina-Díaz I.M., Ponce-Ruíz N., Rojas-García A.E., Zambrano-Zargoza J.F., Bernal-Hernández Y.Y., González-Arias C.A., Barrón-Vivanco B.S., Herrera-Moreno J.F. The relationship between cancer and paraoxonase 1. Antioxidants (Basel), 2022, vol. 11, no. 4, pp. 697. DOI: 10.3390/antiox11040697.
Full-text article (in Russian)